Teva Pharmaceutical Industries Limited’s (TEVA) stock has declined 10% in a month despite strong third-quarter results announced earlier this month. The company beat estimates for earnings as well as sales. The company also slightly raised its earnings and sales guidance. The stock probably declined as investors were not impressed with the guidance increase. However, some analysts believe the stock’s decline after the results was an overreaction.Teva is the world’s largest generic drug company in terms of b ...